Heat Biologics, Inc is a biotechnology business with stocks listed in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Heat Biologics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Heat Biologics. Find the share by name or ticker symbol: HTBX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heat Biologics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Heat Biologics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Heat Biologics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Heat Biologics key stats
- Compare share trading platforms
- Is Heat Biologics stock a buy or sell?
- Heat Biologics performance over time
- Can I short Heat Biologics shares?
- Heat Biologics's financials
- How volatile are Heat Biologics shares?
- Does Heat Biologics pay a dividend?
- Have Heat Biologics shares ever split?
- Other common questions
Heat Biologics share priceUse our graph to track the performance of HTBX stocks over time.
Heat Biologics shares at a glance
|52-week range||USD$0.195 - USD$4.3|
|50-day moving average||USD$1.4406|
|200-day moving average||USD$1.073|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.654|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Heat Biologics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Heat Biologics financials
|Revenue TTM||US$3.5 million|
|Gross profit TTM||US$-9,964,500|
|Return on assets TTM||-25.3%|
|Return on equity TTM||-59.43%|
|Market capitalisation||US$194.7 million|
TTM: trailing 12 months
Shorting Heat Biologics shares
There are currently 7.8 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 53% up from 5.1 million last month.
There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.
Heat Biologics's "short interest ratio" (SIR)
Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 18.2 million). Heat Biologics's SIR currently stands at 0.43. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 430 shares are currently held short.
However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 50 shares are currently held short) or 0.0515% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.
Find out more about how you can short Heat Biologics stock.
Heat Biologics share dividends
We're not expecting Heat Biologics to pay a dividend over the next 12 months.
Have Heat Biologics's shares ever split?
Heat Biologics's shares were split on a 1:10 basis on 21 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.
Heat Biologics share price volatility
Over the last 12 months, Heat Biologics's shares have ranged in value from as little as US$0.195 up to US$4.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.4331. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).
Heat Biologics overview
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Frequently asked questions
Ask an Expert